Does quantification of USPIO uptake-related signal loss allow differentiation of benign and malignant normal-sized pelvic lymph nodes?

Contrast Media and Molecular Imaging

Volumn 7, Issue 3, 2012, Pages 346-355

  Froehlich, Johannes M ^a   Triantafyllou, Maria ^a   Fleischmann, Achim ^b   Vermathen, Peter ^a   Thalmann, George N ^a   Thoeny, Harriet C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bladder cancer; Cellular imaging; Cellular targeting; Contrast agents; Lymph node; Lymphatic metastasis; MRI; Prostate cancer; Superparamagnetic agents

Indexed keywords

ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTIOCYTOSIS; HISTOPATHOLOGY; HUMAN; INGUINAL LYMPH NODE; LIPOMATOSIS; LYMPH NODE HYPERPLASIA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR IMAGING; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SIGNAL NOISE RATIO; STATISTICAL SIGNIFICANCE; TARGET CELL;

ADULT; AGED; CONTRAST MEDIA; DEXTRANS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MIDDLE AGED; PELVIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; ROC CURVE; URINARY BLADDER NEOPLASMS;

EID: 84860364938     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.503     Document Type: Article

References (44)

1. Walsh PC. Surgery and the reduction of mortality from prostate cancer. New Engl J Med 2002; 347: 839-840.
2. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE. Pelvic lymph node dissections in prostate cancer. Eur Urol 2009; 55: 1251-1265.
3. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ. Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing prostatectomy with watchful waiting in early prostate cancer. New Engl J Med 2002; 347: 781-789.
4. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006; 24: 2735-2742.
5. Miki J, Egawa S. The role of lymph node dissection in the management of prostate cancer. Int J Clin Oncol 2011; 16: 195-202.
6. Adams J, Cheng L. Lymph node-positive prostate cancer: current issues, emerging technology and impact on clinical outcome. Expert Rev Anticancer Ther 2011; 11: 1457-1469.
7. Hricak H. Urologic cancer. Methods of early detection and future developments. Cancer 1987; 60(3 suppl): 677-685.
8. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MRI of the prostate: clinical relevance and emerging applications. J Magn Reson Imag 2011; 33: 258-274.
9. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243: 28-53.
10. Paño B, Sebastià C, Buñesch L, Mestres J, Salvador R, Macias NG, Nocolau C. Pathways of lymphatic spread in male urogenital pelvic malignancies. Radiographics 2011; 31: 135-160.
11. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002; 168: 514-518.
12. Fleischmann A, Schobinger S, Markwalder R, Schumacher M, Burkhard F, Thalmann GN, Studer UE. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival. Histopathology 2008; 53: 468-475.
13. Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 2009; 69: 352-262.
14. Kothari PS, Scardino PT, Ohori M, Kattan MW, Wheeler TM. Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol 2001; 25: 1429-1432.
15. Saokar A, Islam T, Jantsch M, Saksena MA, Hahn PF, Harisinghani MG. Detection of lymph nodes in pelvic malignancies with computed tomography and magnetic resonance imaging. Clin Imag 2010; 34: 361-366.
16. Anzai Y, Blackwell KE, Hirschowitz SL, Rogers JW, Sato Y, Yuh WT, Runge VM, Morris MR, McLachlan SJ, Lufkin RB. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in partients with head and neck cancer. Radiology 1994; 192: 709-715.
17. Harisinghani MG, Saini S, Slater GJ, Schnall MD, Rifkin MD. MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): preliminary observations. J Magn Reson Imag 1997; 7: 161-163.
18. Nguyen BC, Stanford W, Thompson BH, Rossi NP, Kernstine KH, Kern JA, Robinson RA, Amorosa JK, Mammone JF, Outwater EK. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imag 1999; 10: 468-473.
19. Bellin MF, Roy C, Kinkel K, Thoumas D, Zaim S, Vanel D, Tuchmann C, Richard F, Jacqmin D, Delcourt A, Chalier E, Lebret T, Cluzel P. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - initial clinical experience. Radiology 1998; 207: 799-808.
20. Pannu HK, Wang KP, Borman TL, Bluemke DA. MR Imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. J Magn Reson Imag 2000; 12(6): 899-904.
21. Sigal R, Vogl T, Casselman J, Moulin G, Veillon F, Hermans R, Dubrulle F, Viala J, Bosq J, Mack M, Depondt M, Mattelaer C, Petit P, Champsaur P, Riehm S, Dadashitazehozi Y, de Jaegere T, Marchal G, Chevalier D, Lemaitre L, Kubiak C, Helmberger R, Halimi P. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR) - results of a phase III multicenter clinical trial. Eur Radiol 2002; 12: 1104-1113.
22. Michel SC, Keller TM, Fröhlich JM, Fink D, Caduff R, Seifert B, Marincek B, Kubik-Huch RA. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002; 225: 527-536.
23. Hudgins PA, Anzai Y, Morris MR, Lucas MA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol 2002; 23: 649-656.
24. Stets C, Brandt S, Wallis F, Buchmann J, Gilbert FJ, Heywang-Köbrunner SH. Axillary lymph node metastases: a statistical analysis of various parameters in MRI with USPIO. J Magn Reson Imag 2002; 16: 60-68.
25. Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P, Saini S, Maravilla KR, Feldman DE, Schmiedl UP, Brunberg JA, Francis IR, Harms SE, Som PM, Tempani CM. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003; 228: 777-788.
26. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. New Engl J Med 2003; 348: 2491-2499.
27. Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, Hulsbergen van de Kaa CA, Kaufmann D, Barentsz JO. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233: 449-456.
28. Keller TM, Michel SC, Fröhlich J, Fink D, Caduff R, Marincek B, Kubik-Huch RA. USPIO-enhanced MRI for preoperative staging of gynecological pelvic tumors: preliminary results. Eur Radiol 2004; 14: 937-944.
29. Koh DM, Brown G, Temple L, Raja A, Toomey P, Bett N, Norman AR, Husband JE. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathological findings - initial observations. Radiology 2004; 231: 91-99.
30. Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR, Oram DH, Jacobs U, Shepherd JH, Reznek RH. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23: 2813-2821.
31. 2*-weighted MR imaging at 1.5 and 3.0 T: early experience. Radiology 2006; 239: 481-487.
32. Memarsadeghi M, Riedl CC, Kaneider A, Galid A, Rudas M, Matzek W, Helbich TH. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus USPIO-enhanced MR imaging. Radiology 2006; 241: 367-377.
33. Harisinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, Weissleder R. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol 2006; 186: 144-148.
34. Curvo-Semedo L, Diniz M, Miguéis J, Juliâo MJ, Martins P, Pinto A, Caseiro-Alves F. USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer. J Magn Reson Imag 2006; 24: 123-131.
35. Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, Severens JL, Adang EM, van der Kaa CH, Fütterer JJ, Barentsz J. MRI with a lymph-node specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008; 9: 850-856.
36. Heesakkers RA, Jager GJ, Hövels AM, de Hoop B, van den Bosch HC, Raat F, Witjes JA, Mulders PF, van der Kaa CH, Barentsz JO. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MRI imaging. Radiology 2009; 251: 408-414.
37. Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imag 2009; 33: 301-305.
38. Kimura K, Tanigawa N, Matsuki M, Nohara T, Iwanmoto M, Sumyoshi K, Tanaka S, Takahashi Y, Narumi Y. High-resolution MR lymphography using ultrasmall superparamagnetic iron oxide (USPIO) in the evaluation of axillary lymph nodes in patients with early stage breast cancer: preliminary results. Breast Cancer 2010; 17: 241-246.
39. Koh DM, George C, Temple L, Collins DJ, Toomey P, Raja A, Bett N, Farhat S, Husband JE, Brown G. Diagnostic accuracy of nodal enhancement pattern of rectal cancer at MRI enhanced with ultrasmall superparamagnetic iron oxide: findings in pathologically matched mesorectal lymph nodes. AJR Am J Roentgenol 2010; 194: W505-W513.
40. Decision of European Medicines Agency concerning Sinerem (USPIO) - updated 17 April 2011. Available from:
41. Lefèvre S, Ruimy D, Jehl F, Neuville A, Robert P, Sordet C, Ehlinger M, Dietermann JL, Bierry G. Septic arthritis: monitoring with USPIO-enhanced macrophage MR imaging. Radiology 2011; 258: 722-728.
42. Taupitz M, Schmitz S, Hamm B. Superparamagnetic iron oxide particles: current state and future development. Rofo 2003; 175(6): 752-765.
43. Saksena M, Harisinghani M, Hahn P, Kim J, Saokar A, King B, Weissleder R. Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers. AJR Am J Roentgenol 2006; 187: W582-W588.
44. Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, Fleischmann A, Vermathen P, Studer UE. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009; 55: 761-769.